• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

静脉血栓栓塞症患者不良结局、大出血和全因死亡率的危险因素

Risk Factors of Unfavorable Outcomes, Major Bleeding, and All-Cause Mortality in Patients with Venous Thromboembolism.

作者信息

Lee Han Young, Yeo Tae Hoon, Heo Tae Kyung, Cho Young Gyu, Cho Dong Hui, Lee Kyung Bok

机构信息

Department of Surgery, Seoul Medical Center, Seoul, Korea.

Department of Surgery, Dongguk University Ilsan Hospital, Goyang, Korea.

出版信息

Vasc Specialist Int. 2021 Dec 31;37:46. doi: 10.5758/vsi.210041.

DOI:10.5758/vsi.210041
PMID:35008065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8752336/
Abstract

PURPOSE

This study aimed to analyze the clinical outcomes of venous thromboembolism (VTE) patients and identify the risk factors for VTE-related unfavorable outcomes, major bleeding, and 30-day all-cause mortality.

MATERIALS AND METHODS

From January 2016 to December 2020, 198 patients with confirmed VTE were enrolled. Potential risk factors for unfavorable outcomes, major bleeding, and all-cause mortality were analyzed.

RESULTS

VTE-related unfavorable outcomes developed in 13.1%, while 30-day all-cause mortality was 8.6%. In the multivariate analysis, a pulse ≥110/min and respiratory rate ≥30/min were statistically significant predictors for VTE-related unfavorable outcomes. Diabetes was a significant risk factor for major bleeding. In addition, a history of malignancy, no anticoagulation treatment, and need for mechanical ventilation were significant predictors of all-cause mortality.

CONCLUSION

VTE-related mortality and morbidity rates remained high. In cases of tachycardia and tachypnea, early aggressive treatment is needed to prevent unfavorable outcomes. Patients with risk factors should be closely monitored.

摘要

目的

本研究旨在分析静脉血栓栓塞症（VTE）患者的临床结局，并确定VTE相关不良结局、大出血和30天全因死亡率的危险因素。

材料与方法

2016年1月至2020年12月，纳入198例确诊VTE患者。分析不良结局、大出血和全因死亡率的潜在危险因素。

结果

13.1%出现VTE相关不良结局，30天全因死亡率为8.6%。多因素分析中，脉搏≥110次/分钟和呼吸频率≥30次/分钟是VTE相关不良结局的统计学显著预测因素。糖尿病是大出血的显著危险因素。此外，恶性肿瘤病史、未进行抗凝治疗和需要机械通气是全因死亡率的显著预测因素。

结论

VTE相关死亡率和发病率仍然很高。对于心动过速和呼吸急促的病例，需要早期积极治疗以预防不良结局。应密切监测有危险因素的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6001/8752336/8458341f56b7/vsi-37-46-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6001/8752336/0427148c243e/vsi-37-46-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6001/8752336/8458341f56b7/vsi-37-46-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6001/8752336/0427148c243e/vsi-37-46-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6001/8752336/8458341f56b7/vsi-37-46-f2.jpg

相似文献

1
Risk Factors of Unfavorable Outcomes, Major Bleeding, and All-Cause Mortality in Patients with Venous Thromboembolism.静脉血栓栓塞症患者不良结局、大出血和全因死亡率的危险因素
Vasc Specialist Int. 2021 Dec 31;37:46. doi: 10.5758/vsi.210041.
2
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.癌症患者静脉血栓栓塞症长期治疗的抗凝治疗
Cochrane Database Syst Rev. 2014 Jul 8(7):CD006650. doi: 10.1002/14651858.CD006650.pub4.
3
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.皮下注射普通肝素用于静脉血栓栓塞症的初始治疗。
Cochrane Database Syst Rev. 2017 Feb 14;2(2):CD006771. doi: 10.1002/14651858.CD006771.pub3.
4
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.复发性静脉血栓栓塞和大出血的病死率与阿司匹林、华法林和直接口服抗凝剂用于二级预防相关。
Thromb Res. 2015 Feb;135(2):243-8. doi: 10.1016/j.thromres.2014.10.033. Epub 2014 Dec 2.
5
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.系统评价：静脉血栓栓塞症患者治疗后复发静脉血栓栓塞和大出血事件的病死率。
Ann Intern Med. 2010 May 4;152(9):578-89. doi: 10.7326/0003-4819-152-9-201005040-00008.
6
Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.静脉血栓栓塞和大出血是否可以作为肺癌死亡率的指标？一项全国性数据库研究。
BMC Cancer. 2020 May 24;20(1):461. doi: 10.1186/s12885-020-06930-1.
7
Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.静脉血栓栓塞症伴或不伴慢性肾脏病患者结局的评估。
JAMA Netw Open. 2020 Oct 1;3(10):e2022886. doi: 10.1001/jamanetworkopen.2020.22886.
8
Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism.静脉血栓栓塞复发中危患者血栓形成复发和大出血的危险因素。
J Thromb Thrombolysis. 2022 Jan;53(1):182-190. doi: 10.1007/s11239-021-02520-5. Epub 2021 Jul 6.
9
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.静脉血栓栓塞症女性在抗凝治疗期间比男性更容易出血吗？来自真实生活、前瞻性START登记研究的数据。
Ther Adv Drug Saf. 2021 Dec 16;12:20420986211062965. doi: 10.1177/20420986211062965. eCollection 2021.
10
Venous Thromboembolism and Renal Impairment: Insights from the SWIss Venous ThromboEmbolism Registry (SWIVTER).静脉血栓栓塞和肾脏损害：来自瑞士静脉血栓栓塞注册研究（SWIVTER）的见解。
Semin Thromb Hemost. 2019 Nov;45(8):851-858. doi: 10.1055/s-0039-1698770. Epub 2019 Oct 17.

引用本文的文献

1
Anterior cruciate ligament tear increases the risk of venous thromboembolism: a population-based cohort study.前交叉韧带撕裂增加静脉血栓栓塞风险：基于人群的队列研究。
Knee Surg Sports Traumatol Arthrosc. 2023 May;31(5):1805-1814. doi: 10.1007/s00167-022-07097-x. Epub 2022 Aug 19.

本文引用的文献

1
Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy.下肢深静脉血栓形成的诊断：一项关于检测准确性的系统评价和荟萃分析
Blood Adv. 2020 Apr 14;4(7):1250-1264. doi: 10.1182/bloodadvances.2019000960.
2
Venous Thromboembolism: Advances in Diagnosis and Treatment.静脉血栓栓塞症：诊断与治疗的进展。
JAMA. 2018 Oct 16;320(15):1583-1594. doi: 10.1001/jama.2018.14346.
3
Venous thromboembolism: Past, present and future.静脉血栓栓塞症：过去、现在和未来。
Thromb Haemost. 2017 Jun 28;117(7):1219-1229. doi: 10.1160/TH16-10-0823. Epub 2017 Jun 8.
4
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.抗栓治疗 VTE 疾病：CHEST 指南和专家小组报告。
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
5
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.新型口服抗凝药：与维生素K拮抗剂相比，它们在预防和治疗血栓栓塞事件患者中的优缺点。
Ther Clin Risk Manag. 2015 Jun 24;11:967-77. doi: 10.2147/TCRM.S84210. eCollection 2015.
6
Current venous thromboembolism management and outcomes in Japan.日本目前的静脉血栓栓塞管理及治疗结果
Circ J. 2014;78(3):708-17. doi: 10.1253/circj.cj-13-0886. Epub 2014 Jan 7.
7
Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort.真实世界人群中静脉血栓栓塞症的发生率和死亡率：Q-VTE 研究队列。
Am J Med. 2013 Sep;126(9):832.e13-21. doi: 10.1016/j.amjmed.2013.02.024. Epub 2013 Jul 3.
8
Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER).老年急性静脉血栓栓塞症患者住院死亡率的预测因素：瑞士静脉血栓栓塞登记处（SWIVTER）。
Eur Heart J. 2012 Apr;33(7):921-6. doi: 10.1093/eurheartj/ehr392. Epub 2011 Oct 27.
9
Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy.静脉血栓栓塞症（VTE）治疗后的死亡率和复发率：具有良好预期寿命的患者的长期随访。
Thromb Res. 2011 Jun;127(6):540-6. doi: 10.1016/j.thromres.2011.02.017. Epub 2011 Mar 24.
10
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.希美加群与低分子量肝素及华法林治疗深静脉血栓形成的随机对照试验
JAMA. 2005 Feb 9;293(6):681-9. doi: 10.1001/jama.293.6.681.